Education
About Us
Working with TipRanks
Follow Us
Sorrento Therapeutics (SRNE)
OTHER OTC:SRNE
Total Valuation
Sorrento Therapeutics has a market cap or net worth of $606.41K. The enterprise value is ―.
Market Cap$606.41K
Enterprise Value―
Share Statistics
Sorrento Therapeutics has 551,281,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding551,281,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sorrento Therapeutics’s return on equity (ROE) is 30.79 and return on invested capital (ROIC) is -286.80%.
Return on Equity (ROE)30.79
Return on Assets (ROA)-1.21
Return on Invested Capital (ROIC)-286.80%
Return on Capital Employed (ROCE)-3.48
Revenue Per Employee66.22K
Profits Per Employee-608.81K
Employee Count949
Asset Turnover0.13
Inventory Turnover3.35
Valuation Ratios
The current PE Ratio of Sorrento Therapeutics is >-0.01. Sorrento Therapeutics’s PEG ratio is ―.
PE Ratio>-0.01
PS Ratio0.00
PB Ratio-0.02
Price to Fair Value-0.20
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio―
Income Statement
In the last 12 months, Sorrento Therapeutics had revenue of 62.84M and earned -572.84M in profits. Earnings per share was -1.37.
Revenue62.84M
Gross Profit29.39M
Operating Income-504.31M
Pretax Income-561.75M
Net Income-572.84M
EBITDA-539.93M
Earnings Per Share (EPS)-1.37
Cash Flow
In the last 12 months, operating cash flow was -234.63M and capital expenditures -8.59M, giving a free cash flow of -243.21M billion.
Operating Cash Flow-234.63M
Free Cash Flow-243.21M
Free Cash Flow per Share-0.44
Dividends & Yields
Sorrento Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-4.53
52-Week Price Change0.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)128.87K
Important Dates
Sorrento Therapeutics upcoming earnings date is Aug 10, 2023, TBA Not Confirmed.
Last Earnings DateMay 15, 2023
Next Earnings DateAug 10, 2023
Ex-Dividend Date―
Financial Position
Sorrento Therapeutics as a current ratio of 0.29, with Debt / Equity ratio of -722.95%
Current Ratio0.29
Quick Ratio0.26
Debt to Market Cap9.53
Net Debt to EBITDA-0.21
Interest Coverage Ratio-58.82
Taxes
In the past 12 months, Sorrento Therapeutics has paid -2.42M in taxes.
Income Tax-2.42M
Effective Tax Rate<0.01
Enterprise Valuation
Sorrento Therapeutics EV to EBITDA ratio is -0.21, with an EV/FCF ratio of -0.37.
EV to Sales1.82
EV to EBITDA-0.21
EV to Free Cash Flow-0.37
EV to Operating Cash Flow-0.39
Balance Sheet
Sorrento Therapeutics has $80.64M in cash and marketable securities with $207.60M in debt, giving a net cash position of $126.97M billion.
Cash & Marketable Securities$80.64M
Total Debt$207.60M
Net Cash$126.97M
Net Cash Per Share$0.23
Tangible Book Value Per Share-$0.57
Margins
Gross margin is 46.77%, with operating margin of -802.55%, and net profit margin of -911.60%.
Gross Margin46.77%
Operating Margin-802.55%
Pretax Margin-893.95%
Net Profit Margin-911.60%
EBITDA Margin-859.22%
EBIT Margin-880.30%
Analyst Forecast
The average price target for Sorrento Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―